Literature DB >> 17899306

Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria.

Umit Dincer1, Engin Cakar, M Zeki Kiralp, Hasan Dursun.   

Abstract

Ankylosing spondylitis (AS) is a chronic, progressive, and disabling disease. Among the rheumatological diseases, the longest diagnosis delay is still found for AS. The aim of this cross-sectional study is to evaluate the diagnosis delay and possible reasons in AS. A secondary aim is to assess the relation between diagnosis delay and some clinical and laboratory features. One hundred eleven AS patients, (103 male, 8 female) were recruited. A face-to-face interview was applied to take medical history, and a questionnaire that contains some clinical aspects of disease was used. Diagnosis delay was described as the gap between first spondiloarthropathic symptom and correct diagnosis of AS. The average of diagnosis delay was 6.05 +/- 5.08 years. The average age of patients at disease onset was 23.18 +/- 9.59, the average disease duration was 10.44 +/- 8.11, and the average age at diagnosis was 27.88 +/- 11.63. The average diagnosis delay was 5. 3 +/- 3.5 in HLA B 27(+) AS patients, whereas it was 9.2 +/- 7.7 in HLA B 27(-) AS patients (p = 0.037). Diagnosis delay in patients with inflammatory back pain (+) (IBP) at disease onset was lower than IBP (-) patients (3.28 +/- 3.32, 8.57 +/- 8.54; respectively) (p = 0.001). The patients having positive family history had lower diagnosis delay than those with negative family history (4.60 +/- 4.44, 10.00 +/- 2.30; respectively) (p = 0.003). The diagnosis delay is a challenge and an important problem for patients with AS and physicians. HLA B27 and family history should be considered while making new criteria. Inflammatory back pain should be emphasized as the main screening criterion for primary care physicians. These clinical and laboratory features had positive effect on the average diagnosis delay in AS patients. Describing new diagnostic criteria, which is more useful to diagnosis of AS, is necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899306     DOI: 10.1007/s10067-007-0727-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

1.  Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis.

Authors:  M A Brown; S H Laval; S Brophy; A Calin
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway.

Authors:  J T Gran; G Husby; M Hordvik
Journal:  Ann Rheum Dis       Date:  1985-06       Impact factor: 19.103

3.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

4.  Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.

Authors:  J C Davis; D M van der Heijde; J Braun; M Dougados; J Cush; D Clegg; R D Inman; A Kivitz; L Zhou; A Solinger; W Tsuji
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

Review 5.  Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Authors:  J Braun; J Sieper; M Breban; E Collantes-Estevez; J Davis; R Inman; H Marzo-Ortega; H Mielants
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

6.  A comparison of patients with spondyloarthropathy seen in specialty clinics with those identified in a communitywide epidemiologic study. Has the classic case misled us?

Authors:  G S Boyer; D W Templin; A Bowler; R C Lawrence; D F Everett; S P Heyse; J Cornoni-Huntley; W P Goring
Journal:  Arch Intern Med       Date:  1997-10-13

7.  Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria.

Authors:  Martin Rudwaleit; Anke Metter; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2006-02

8.  How to diagnose axial spondyloarthritis early.

Authors:  M Rudwaleit; D van der Heijde; M A Khan; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

9.  Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality?

Authors:  A van Tubergen; L Heuft-Dorenbosch; G Schulpen; R Landewé; R Wijers; D van der Heijde; J van Engelshoven; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

10.  Maternal age and family history are risk factors for ankylosing spondylitis.

Authors:  F Javier Jiménez-Balderas; Abraham Zonana-Nacach; M Lourdes Sánchez; Juan O Talavera; Leonor Barile-Fabris; Martha E Pérez-Rodríguez; Jorge Arellano; Antonio Fraga
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

View more
  34 in total

1.  Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis.

Authors:  Klaus Krüger; Ulrich von Hinüber; Florian Meier; Haijun Tian; Katharina Böhm; Steffen M Jugl; Kathrin Borchert; Dominic Meise; Christine König; Sebastian Braun
Journal:  Rheumatol Int       Date:  2018-08-09       Impact factor: 2.631

2.  Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis.

Authors:  Mi Ryoung Seo; Hae Lim Baek; Hyun Hwa Yoon; Hee Jung Ryu; Hyo-Jin Choi; Han Joo Baek; Kwang-Pil Ko
Journal:  Clin Rheumatol       Date:  2014-09-05       Impact factor: 2.980

3.  Recently diagnosed axial spondyloarthritis: gender differences and factors related to delay in diagnosis.

Authors:  Gleb Slobodin; Iris Reyhan; Nina Avshovich; Alexandra Balbir-Gurman; Nina Boulman; Mona Elias; Joy Feld; Reuven Mader; Doron Markovitz; Doron Rimar; Itzhak Rosner; Michael Rozenbaum; Devy Zisman; Majed Odeh
Journal:  Clin Rheumatol       Date:  2011-03-01       Impact factor: 2.980

4.  Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Rachida Bensabbah; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2010-11-26       Impact factor: 2.631

5.  Gender and disease features in Moroccan patients with ankylosing spondylitis.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2011-07-28       Impact factor: 2.980

6.  Prevalence and factors associated with disturbed sleep in outpatients with ankylosing spondylitis.

Authors:  Anliu Nie; Chen Wang; Yuqing Song; Xia Xie; Hui Yang; Hong Chen
Journal:  Clin Rheumatol       Date:  2018-07-03       Impact factor: 2.980

7.  Clinical patterns and characteristics of ankylosing spondylitis in China.

Authors:  Qiaoxia Qian; Xia Xu; Hongjun He; Hengdong Ji; Hui Zhang; Yue Ding; Sheng-Ming Dai; Yaohong Zou; Qi Zhu; Chengde Yang; Shuang Ye; Lindi Jiang; Jian-Ping Tang; Qiang Tong; Dongyi He; Dongbao Zhao; Yuan Li; Yanyun Ma; Jingru Zhou; Ziyu Yuan; Juan Zhang; Li Jin; Xiaodong Zhou; John D Reveille; Hejian Zou; Jiucun Wang
Journal:  Clin Rheumatol       Date:  2017-05-27       Impact factor: 2.980

8.  Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes--an Indian perspective.

Authors:  Rohit Aggarwal; Anand N Malaviya
Journal:  Clin Rheumatol       Date:  2008-12-04       Impact factor: 2.980

9.  Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome-wide expression profiling and real-time polymerase chain reaction.

Authors:  Jieruo Gu; Yu-Ling Wei; James C C Wei; Feng Huang; Ming-Shiou Jan; Michael Centola; Mark B Frank; David Yu
Journal:  Arthritis Rheum       Date:  2009-11

10.  Impact of gender, work, and clinical presentation on diagnostic delay in Italian patients with primary ankylosing spondylitis.

Authors:  F Bandinelli; G Salvadorini; A Delle Sedie; L Riente; S Bombardieri; M Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2015-08-04       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.